PLANTATION, Fla., Dec. 12, 2008 (GLOBE NEWSWIRE) -- Goodwin Biotechnology Inc. (GBI) announced today the successful completion of the development work for the new AREVA drug that will be radio-labeled by the NCI with lead-212 and used to fight cancer. The completion of this step allows for the cGMP manufacturing of the conjugated drug that is expected to enter a Phase I clinical trial in 2009.

Stephanie Finnegan, CEO of GBI said "We are proud that AREVA chose us to play a key role in this new generation of radioimmunotherapy and we look forward to an auspicious beginning of the clinical trials."

About Goodwin Biotechnology Inc.

GBI is one of the first established biopharmaceutical contract manufacturing organizations (CMOs), established in 1992. GBI specializes in process development and cGMP compliant mammalian cell culture manufacturing of bio-therapeutics for pre-clinical studies through Phase III clinical trials. GBI's clients include small to midsized biotech companies throughout North America and Europe, universities, renowned cancer research institutes and various branches of the U.S. government. GBI offers its clients the depth of experience of an established US Contract Manufacturing Organization.

The Goodwin Biotechnology Inc. logo is available at

About AREVA Inc.

With manufacturing facilities in 43 countries and a sales network in more than 100, AREVA offers customers reliable technological solutions for CO2-free power generation and electricity transmission and distribution. We are the world leader in nuclear power and the only company to cover all industrial activities in this field. Our 71,000 employees are committed to continuous improvement on a daily basis, making sustainable development the focal point of the group's industrial strategy. AREVA's businesses help meet the 21st century's greatest challenges: making energy available to all, protecting the planet, and acting responsibly towards future generations.

The AREVA Inc. logo is available at

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

Patrick Bourdet 
(301) 841-1600

4800 Hampden Lane, Suite 1100
Bethesda, Maryland 20814

Goodwin Biotechnology Inc.
Stephanie Finnegan, CEO
(954) 327-9606

1850 NW 69 Avenue
Plantation, Florida 33313